November 15, 2026 · Phase 2 readout
BNTX Phase 2 readout: a negative outcome, -8.4%
-8.4%BioNTech SE (BNTX) →
On November 15, 2026, RO7198457 intravenous (IV) — BioNTech SE (Colorectal Cancer Stage II) reached its Phase 2 readout. The result was a negative outcome, and the stock moved -8.4% in the window around the event. It had already run +22.7% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$111.40
1d before
$102.07
Event day
$102.07
1d after
$103.81
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.6% expected); the stock actually moved -8.4%. Model confidence at the time: 100%.
See the full scored track recordPre-catalyst setup
+22.7%
30-day run-up
7997%
30-day volatility
1.0×
volume spike
